Explore
Trendline
Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments
Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments
Read More
Trendline
Diakonos Oncology Receives FDA Fast Track Designation for Melanoma Treatment
Diakonos Oncology Receives FDA Fast Track Designation for Melanoma Treatment
Read More
Trendline
EyePoint Reports Q1 2026 Financial Results and Advances in Retinal Disease Therapies
EyePoint Reports Q1 2026 Financial Results and Advances in Retinal Disease Therapies
Read More
Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Read More
Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026
Nuvectis Pharma Reports Increased Net Loss in Q1 2026
Read More
Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Read More
Trendline
Cytospire Secures $83 Million for Innovative T-Cell Engager Platform
Cytospire Secures $83 Million for Innovative T-Cell Engager Platform
Read More
Trendline
Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark
Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark
Read More
Trendline
IDEAYA Biosciences Reports Positive Trial Results and Financial Update for Q1 2026
IDEAYA Biosciences Reports Positive Trial Results and Financial Update for Q1 2026
Read More
Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Read More
Trendline
Curis to Announce Q1 2026 Financial Results and Host Webcast
Curis to Announce Q1 2026 Financial Results and Host Webcast
Read More
Trendline
Innate Pharma Schedules Q1 2026 Business Update Conference Call
Innate Pharma Schedules Q1 2026 Business Update Conference Call
Read More
